Ayati Devices raises $1.5M to scale diabetic foot diagnostics
What's the deal? Bengaluru-based medical technology startup Ayati Devices has raised Rs 15 crore ($1.5 million) in a Series A round led by Inflexor VenturesDealroom has a profile for this one. Try Dealroom →. The company builds portable, point-of-care diagnostic devices for diabetic foot complications and peripheral vascular disease.
Who's behind it? Founded in 2019 by Nishant Kathpal, Ayati Devices was incubated at IIT Bombay's Society for Innovation and Entrepreneurship (SINE)Dealroom has a profile for this one. Try Dealroom →. Its devices are designed to make early screening accessible beyond tertiary hospitals.
What's the endgame? The funds will accelerate commercialisation, expand domestic and international presence, strengthen manufacturing, and increase investment in research and artificial intelligence. Ayati says its solutions have enabled more than 1 million screenings, with over 10,000 devices deployed across 30 countries.
The product: Its portfolio spans multiple stages of diabetic foot assessment. Vibrasense measures vibration perception to detect large-fibre neuropathy; Vasosense screens for peripheral artery disease; and Angiocam enables real-time tissue perfusion imaging. The PODIA Trolley offers a pay-per-test model to cut upfront costs for healthcare providers.
Why it matters: Flagship device Vibrasense has undergone clinical evaluation. A study of 562 people with type 2 diabetes compared its vibration perception threshold testing with conventional biothesiometry and nerve conduction studies for screening diabetic peripheral neuropathy.
The signal: The round marks a step up for Ayati as it moves from deployment to scaled commercialisation. Portable point-of-care diagnostics are gaining traction as a way to bring early screening to settings without specialist infrastructure.
Read more: Entrackr
Image credit: Generated with Gemini
